Treatment for Occlusion

Phase-Based Progress Estimates
Rutgers School of Dental Medicine, Newark, NJ
18 - 65
All Sexes
What conditions do you have?

Study Summary

This trial will test a new injection for TMJ pain in 20 people. Outcomes will be measured by force and electrical activity in the jaw muscles, and participants will be surveyed about their experience. This treatment is used to treat Occlusion. No patients in this trial will be given a placebo instead of the treatment.

Treatment Effectiveness

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: Baseline, 30 min, 2 hours and 2 weeks

Week 2
Week 2
Change in Bite force distribution
Change in Surface EMG

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

0 Treatment Group

20 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · Phase 2

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 30 min, 2 hours and 2 weeks
Closest Location: Rutgers School of Dental Medicine · Newark, NJ
Photo of new jersey 1Photo of new jersey 2Photo of new jersey 3
2013First Recorded Clinical Trial
1 TrialsResearching Occlusion
2 CompletedClinical Trials

Who is running the clinical trial?

Rutgers, The State University of New JerseyLead Sponsor
362 Previous Clinical Trials
59,931 Total Patients Enrolled
Gayathri D Subramanian, DMDPrincipal InvestigatorRutgers School of Dental Medicine

Eligibility Criteria

Age 18 - 65 · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are younger than 18 years of age.
You are of any ethnicity.
You are male or female.
You have pain in your jaw or temple on either side of the face in the last 30 days.
You have a stiff or painful jaw in the last 30 days.
You have experienced pain in the jaw/temple region during the last 30 days.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.